Showing results (41-50 of 75) with videos related to
Sort By:
Pageof 8
Gut|April 8, 2011
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitisKeith Leiper, Kate Martin, Anthony Ellis, et al.Medicine|March 1, 2019
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE studyFraser Cummings, Daniel R Gaya, Scott Levison, et al.Inflammatory Bowel Diseases|April 4, 2015
Killing of Escherichia coli by Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by Hydroxychloroquine and Vitamin DPaul K Flanagan, Direkrit Chiewchengchol, Helen L Wright, et al.Digestive Diseases and Sciences|November 27, 2022
Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease PatientsGerum Gashaw Gebeyehu, Joseph Fiske, Eleanor Liu, et al.Inflammatory Bowel Diseases|August 3, 2024
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease PatientsGerum Gashaw Gebeyehu, Giacomo Broglio, Eleanor Liu, et al.Inflammatory Bowel Diseases|October 18, 2007
Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamineSreedhar Subramanian, Jonathan M Rhodes, C Anthony Hart, et al.Inflammatory Bowel Diseases|March 15, 2018
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative ColitisPeter M Irving, Tariq Iqbal, Chuka Nwokolo, et al.Journal of Crohn'S & Colitis|January 29, 2016
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim ResultsAxel Dignass, Ayesha Akbar, Ailsa Hart, et al.Gastroenterology|October 9, 2007
Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's diseaseChiedzo M Mpofu, Barry J Campbell, Sreedhar Subramanian, et al.Crohn'S & Colitis 360|July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohortMohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.Pageof 8